Redox Switches Amplified Alzheimer’s Neuroinflammation

Redox Switches Amplified Alzheimer’s Neuroinflammation

TL;DR: A 2026 study in Cell Chemical Biology found that alzheimer’s inflammation may be driven by a specific chemical switch: S-nitrosylation of STING at cysteine 148, which pushed innate immune signaling toward synaptic damage. Key Findings STING carried the redox switch: The study identified S-nitrosylation of human STING at cysteine 148 as a redox modification …

Read more

Midlife Vitamin D Linked to Lower Brain Tau Decades Later

Midlife Vitamin D Linked to Lower Brain Tau Decades Later

TL;DR: A 2026 study in Neurology Open Access found that in 793 dementia-free adults, higher vitamin D levels around age 39 were associated with less tau readout on PET brain imaging about 16 years later, while amyloid beta did not show the same relationship. Key Findings 793 dementia-free adults: Participants had vitamin D measured in …

Read more

Three Blood p-tau217 Tests All Nailed Alzheimer’s Diagnosis

Three Blood p-tau217 Tests All Nailed Alzheimer's Diagnosis

TL;DR: A 2026 study in Translational Psychiatry found that three different plasma p-tau217 assays separated Alzheimer’s dementia from controls and frontotemporal degeneration with excellent accuracy, shifting the test from whether the marker works to which platform clinics can deploy. Key Findings Three p-tau217 assays all performed strongly: The cohort included 39 cognitively unimpaired controls, 28 …

Read more

Chemotherapy Neuropathy Review Links Pain to Brain Changes

Chemotherapy Neuropathy Review Links Pain to Brain Changes

TL;DR: A 2026 review in Reviews in the Neurosciences argues that chemotherapy-induced peripheral neurotoxicity (CIPN), nerve injury from cancer treatment, can involve central nervous system changes that help explain chronic neuropathic pain and chemotherapy-related cognitive impairment. Key Findings 70-80% during treatment: The review cites chemotherapy-induced peripheral neurotoxicity as affecting about 70-80% of patients during treatment. …

Read more

Orbitofrontal Atrophy Rating Improved bvFTD Diagnostic Certainty

Orbitofrontal Atrophy Rating Improved bvFTD Diagnostic Certainty

TL;DR: A 2026 Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring study found that orbitofrontal and frontoinsular visual rating scales on MRI helped distinguish possible from probable behavioral variant frontotemporal dementia. Key Findings bvFTD cohort: The study included 93 probable and 15 possible bvFTD patients, plus healthy controls for cross-sectional comparisons. Best regions: Orbitofrontal and …

Read more

Alzheimer’s Capillary Blood Biomarkers Correlated With Cognition

Alzheimer's Capillary Blood Biomarkers Correlated With Cognition

TL;DR: A 2026 study in Nature Communications found that self-administered finger-prick blood tests for phosphorylated tau 217 (p-tau217), an Alzheimer’s tau marker, and glial fibrillary acidic protein (GFAP), an astrocyte-injury marker, correlated with cognition and function in older adults. Key Findings Remote sampling: Participants used capillary finger-prick blood collection rather than standard clinic-based venous blood …

Read more

Anxiety in ALS Was Driven Mostly by Depression Symptoms

Anxiety in ALS Was Driven Mostly by Depression Symptoms

TL;DR: A 2026 BJPsych Open study found clinically significant anxiety in about 18% of non-demented ALS patients for state anxiety and 14% for trait anxiety, with anxiety scores driven mainly by cognitive-affective depression symptoms rather than motor severity. Key Findings ALS cohort: The study compared 433 non-demented ALS patients with 313 healthy controls. State anxiety: …

Read more

White Matter Hyperintensities Tracked ALS Progression and Survival

White Matter Hyperintensities Tracked ALS Progression and Survival

TL;DR: A 2026 medRxiv preprint found that white matter hyperintensity (WMH) burden, the amount of MRI-visible white-matter injury, was greater and progressed faster in amyotrophic lateral sclerosis (ALS), with progression tied to worse motor and cognitive scores. Key Findings 369-person MRI sample: Researchers analyzed 204 ALS patients and 165 healthy controls from the Canadian ALS …

Read more

GLP-1 Agonists Showed Dose-Specific ON-Medication Motor Effects in Parkinson’s Disease

GLP-1 Agonists Showed Dose-Specific ON-Medication Motor Effects in Parkinson's Disease

TL;DR: A 2026 systematic review and exploratory network meta-analysis of 5 randomized trials in Neurological Sciences found dose-specific ON-medication motor improvements, measured while usual Parkinson’s drugs were active, for some GLP-1 receptor agonists, glucose-related metabolic hormone drugs, in Parkinson’s disease, but broader motor, non-motor, and quality-of-life evidence remained limited. Key Findings 5 randomized trials: The …

Read more

Targeted Memory Reactivation Changed Sleep Waves But Not Motor Retention in Parkinson’s

Targeted Memory Reactivation Changed Sleep Waves But Not Motor Retention in Parkinson’s

TL;DR: A 2026 medRxiv preprint found that targeted memory reactivation (TMR), replaying learned sounds during non-REM sleep, changed spindle and slow-wave density during a nap but did not improve motor memory retention in Parkinson’s disease or healthy older adults. Key Findings Parkinson’s and healthy older adults were compared: The experiment included 20 people with Parkinson’s …

Read more